ACT 247.91 Actavis Inc $ACT Hit a 52 week high of 254.41 Closing the day 11/05/14 at 247.91 +2.59 +1.06% With a day low of 244.14 and a total volume of 3,242,601.
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - 1 hr 46 mins ago
It's bullish news but you can't buy just anything, Cramer says.
ACT: 247.91 (+2.59), LMT: 189.73 (-1.06), XOM: 95.07 (+0.55), ILMN: 186.37 (-5.04), AKS: 6.23 (-0.11), KORS: 72.40 (+0.98), PAYX: 47.77 (+0.52), RIG: 28.89 (+1.54), EOG: 96.10 (+5.82), COST: 136.50 (-0.05), TWTR: 40.37 (-0.53), OXY: 86.47 (+1.15), KO: 42.31 (+0.49), SEAS: 18.70 (+0.17), TMO: 118.55 (+0.23), NUE: 53.06 (+0.19), TRIP: 71.95 (-11.84), DISCA: 34.47 (+1.16), CHUY: 20.68 (-9.49), LB: 75.00 (+0.72), GEO: 39.90 (-0.53), ESV: 40.01 (+1.41), MPC: 90.71 (+0.08), BAX: 70.90 (+2.45), MRK: 59.57 (+0.20), EXPE: 83.05 (-0.84), STI: 39.60 (+0.55)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - 2 hrs 5 mins ago
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), SWKS: 60.88 (+0.46), AKRX: 41.68 (-0.96), SLXP: 139.50 (-0.95), AAPL: 108.86 (+0.26)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 196.32 (+1.20), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 247.91 (+2.59)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), MYL: 53.47 (-0.28), TEVA: 57.79 (-0.20)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), TEVA: 57.79 (-0.20)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 247.91 (+2.59)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 247.91 (+2.59)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 247.91 (+2.59)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 196.32 (+1.20), BIIB: 319.55 (-2.51), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59), JAZZ: 167.18 (-1.30), ALXN: 189.89 (-1.41), CELG: 105.15 (-0.60)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 230.97 (-7.96), ACT: 247.91 (+2.59), FEYE: 29.12 (-5.13), AWAY: 28.58 (-5.17), CYBR: 33.80 (-2.73), JAZZ: 167.18 (-1.30), TRIP: 71.95 (-11.84), PANW: 102.52 (-4.19), ATHM: 44.08 (-6.11)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), ARIA: 5.69 (-0.19), HSP: 53.10 (-0.18)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 247.91 (+2.59), ECYT: 5.50 (-0.20), MRK: 59.57 (+0.20), HSP: 53.10 (-0.18)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 102.77 (-1.06), ACT: 247.91 (+2.59), PRGO: 158.50 (-1.35), ALNY: 88.01 (-1.98)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), HSP: 53.10 (-0.18), KERX: 15.37 (-0.93)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 196.32 (+1.20), TSLA: 230.97 (-7.96), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59), ATHM: 44.08 (-6.11)
Should You Buy Actavis (ACT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:54AM CST
Actavis is seeing favorable earnings estimate revision activity and an earnings beat might be in the cards for the upcoming report.
ACT: 247.91 (+2.59)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.00 (+0.02), AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), SWKS: 60.88 (+0.46), AKRX: 41.68 (-0.96), JAZZ: 167.18 (-1.30), SLXP: 139.50 (-0.95), AAPL: 108.86 (+0.26), ATHM: 44.08 (-6.11)
Can Cognizant (CTSH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 5:12PM CST
Cognizant Technology Solutions Corp (CTSH) is set to report third quarter 2014 results on Nov 5.
ACT: 247.91 (+2.59), DIS: 91.00 (+0.65), ACN: 82.48 (+1.33), CTSH: 52.40 (+3.91)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), ALNY: 88.01 (-1.98), HSP: 53.10 (-0.18)
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - 1 hr 46 mins ago
It's bullish news but you can't buy just anything, Cramer says.
ACT: 247.91 (+2.59), LMT: 189.73 (-1.06), XOM: 95.07 (+0.55), ILMN: 186.37 (-5.04), AKS: 6.23 (-0.11), KORS: 72.40 (+0.98), PAYX: 47.77 (+0.52), RIG: 28.89 (+1.54), EOG: 96.10 (+5.82), COST: 136.50 (-0.05), TWTR: 40.37 (-0.53), OXY: 86.47 (+1.15), KO: 42.31 (+0.49), SEAS: 18.70 (+0.17), TMO: 118.55 (+0.23), NUE: 53.06 (+0.19), TRIP: 71.95 (-11.84), DISCA: 34.47 (+1.16), CHUY: 20.68 (-9.49), LB: 75.00 (+0.72), GEO: 39.90 (-0.53), ESV: 40.01 (+1.41), MPC: 90.71 (+0.08), BAX: 70.90 (+2.45), MRK: 59.57 (+0.20), EXPE: 83.05 (-0.84), STI: 39.60 (+0.55)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - 2 hrs 5 mins ago
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), SWKS: 60.88 (+0.46), AKRX: 41.68 (-0.96), SLXP: 139.50 (-0.95), AAPL: 108.86 (+0.26)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 196.32 (+1.20), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 247.91 (+2.59)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), MYL: 53.47 (-0.28), TEVA: 57.79 (-0.20)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), TEVA: 57.79 (-0.20)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 247.91 (+2.59)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 247.91 (+2.59)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 247.91 (+2.59)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 196.32 (+1.20), BIIB: 319.55 (-2.51), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59), JAZZ: 167.18 (-1.30), ALXN: 189.89 (-1.41), CELG: 105.15 (-0.60)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 230.97 (-7.96), ACT: 247.91 (+2.59), FEYE: 29.12 (-5.13), AWAY: 28.58 (-5.17), CYBR: 33.80 (-2.73), JAZZ: 167.18 (-1.30), TRIP: 71.95 (-11.84), PANW: 102.52 (-4.19), ATHM: 44.08 (-6.11)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), ARIA: 5.69 (-0.19), HSP: 53.10 (-0.18)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 247.91 (+2.59), ECYT: 5.50 (-0.20), MRK: 59.57 (+0.20), HSP: 53.10 (-0.18)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 102.77 (-1.06), ACT: 247.91 (+2.59), PRGO: 158.50 (-1.35), ALNY: 88.01 (-1.98)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), HSP: 53.10 (-0.18), KERX: 15.37 (-0.93)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 196.32 (+1.20), TSLA: 230.97 (-7.96), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59), ATHM: 44.08 (-6.11)
Should You Buy Actavis (ACT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:54AM CST
Actavis is seeing favorable earnings estimate revision activity and an earnings beat might be in the cards for the upcoming report.
ACT: 247.91 (+2.59)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.00 (+0.02), AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), SWKS: 60.88 (+0.46), AKRX: 41.68 (-0.96), JAZZ: 167.18 (-1.30), SLXP: 139.50 (-0.95), AAPL: 108.86 (+0.26), ATHM: 44.08 (-6.11)
Can Cognizant (CTSH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 5:12PM CST
Cognizant Technology Solutions Corp (CTSH) is set to report third quarter 2014 results on Nov 5.
ACT: 247.91 (+2.59), DIS: 91.00 (+0.65), ACN: 82.48 (+1.33), CTSH: 52.40 (+3.91)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 93.50 (-0.59), ACT: 247.91 (+2.59), ALNY: 88.01 (-1.98), HSP: 53.10 (-0.18)
